Search

Now showing items 1-4 of 4

Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.

Baker, D; Giovannoni, G; Schmierer, K (2017-11)

BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Dubuisson, N; Bauer, A; Buckley, M; Gilbert, R; Paterson, A; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Giovannoni, G;... (2017-10)

BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...

The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.

Shribman, S; Hasan, H; Hadavi, S; Giovannoni, G; Noyce, AJ (2018-02)

BACKGROUND: The BRadykinesia Akinesia INcordination (BRAIN) test is an online keyboard-tapping test previously validated as a sensitive tool for detecting signs of Parkinson's disease. OBJECTIVES: To determine whether the ...

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK.

Jacobs, BM; Schalk, L; Dunne, A; Scalfari, A; Nandoskar, A; Gran, B; Mein, CA; Sellers, C; Spilker, C; Rog, D;... (2023-05-17)

PURPOSE: Genetic studies of multiple sclerosis (MS) susceptibility and severity have focused on populations of European ancestry. Studying MS genetics in other ancestral groups is necessary to determine the generalisability ...